Biostatistics Support

Gain stronger clarity in communication with the methodical biostatistics CRO services needed for drug development today!

The MMS team are all superstars! You have delivered to timelines throughout, and we really appreciate it. Thank you!
Satisfied Sponsor
Biometrics Division

Expert biostatisticians at MMS hold the trust of leading pharmaceutical and biotechnology Sponsors. Our biostatistics team has an incomparable, industry-educated skill set and end-game experience to provide support in:

  • Sample size calculations,
  • Randomization schedules,
  • Statistical analysis plans (SAP),
  • Data interpretation,
  • Collaborative solution finding on data/analysis related hurdles, and much more.

When Sponsors engage an MMS biostatistician, they are guaranteed clarity in understanding the statistical rationale and excellent communication with all team members, including programmers, data management, data scientists, medical writers, and clinicians. 

The success of a clinical trial depends on the strength and knowledge of the biostatistics lead. When supporting Sponsors with statistical analyses and protocol development for global health authority responses and/or publication support, the biostatisticians at MMS are experienced, attentive, methodical, and intuitive.

Enhanced Capabilities with Exploristics and KerusCloud

In 2025, MMS expanded its biostatistics and data science expertise through the acquisition of Exploristics, a leading Statistical analytics solutions provider known for innovation in clinical trial design and simulation. This partnership brings the power of KerusCloud, Exploristics’ flagship cloud-based simulation platform, to MMS clients. KerusCloud enables advanced study simulations, allowing researchers to optimize clinical trial designs, reduce risk, and make data-driven decisions with confidence.

With KerusCloud, Sponsors can:

  • Simulate alternate study designs, including novel and complex designs to predict outcomes and mitigate risk and/or accelerate timelines and mitigate cost before trials begin
  • Integrate real-world data into simulations for more robust study planning
  • Streamline the trial design process, saving time and resources

The integration of Exploristics’ expertise further strengthens our ability to provide cutting-edge design expertise and innovative delivery solutions for today’s most complex clinical challenges.

Read the full details in the press announcement here.

What Differentiates MMS From Other CROs?

responsive

MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.

adaptable

MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.

focused

MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.

Suggested For You

webinar

March 26th, 2026

Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 30th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today